Research Analysts’ Updated EPS Estimates for June, 14th (ACCO, AMSC, AMTX, CA, CCS, CLDR, CRTO, CTRV, ENR, ERF)
ACCO Brands (NYSE:ACCO) had its buy rating reaffirmed by analysts at Barrington Research. The firm currently has a $16.00 price target on the stock.
American Superconductor (NASDAQ:AMSC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “American Superconductor Corporation is a leading energy technologies company. The company develops and sells a wide range of products and solutions based on power electronic systems and high temperature superconductor wires that dramatically improve the efficiency, reliability and quality of electricity during its generation, transmission, distribution and use. The company is a dominant force in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world’s principal supplier of HTS wire, AMSC is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, motors, generators, and advanced transportation and defense systems. AMSC also provides utility and industrial customers worldwide with voltage regulation systems that dramatically enhance power grid capacity, reliability and security, as well as industrial productivity. “
Carrefour (EPA:CA) was given a €16.00 ($18.60) price target by analysts at Credit Suisse Group AG. The firm currently has a neutral rating on the stock.
Century Communities (NYSE:CCS) had its outperform rating reissued by analysts at Wedbush. They currently have a $42.00 target price on the stock.
Nomura initiated coverage on shares of Cloudera (NYSE:CLDR). The firm issued a reduce rating and a $12.00 target price on the stock.
Criteo (NASDAQ:CRTO) was downgraded by analysts at Vertical Group from a buy rating to a hold rating.
ContraVir Pharmaceuticals (NASDAQ:CTRV) had its hold rating reiterated by analysts at Maxim Group. The analysts wrote, “Contravir announced that IND for CRV-431 (cyclophilin inhibitor) has been approved to move into the clinic for hepatitis B virus (HBV). Important to note is the design of the study, which in our view could potentially accelerate timelines for the HBV combination; TXL + CRV-431.””
Energizer (NYSE:ENR) had its buy rating reissued by analysts at Jefferies Financial Group Inc. They currently have a $70.00 price target on the stock. The analysts wrote, “Pricing in US batteries has driven ENR’s industry sales growth well above the avg. in HPC/bevs over the latest 52-wks (+3.9% vs. +0.5%). Long thought to be a declining category, improving battery fundamentals should help drive multiple expansion at ENR, which is trading at 10x EV/EBITDA vs. 12.5x peer avg. Recent referral up to Euro Comm. for SPB battery deal does little to change our expectation of a positive outcome. ENR remains our top alpha-generating idea.””
SunTrust Banks, Inc. assumed coverage on shares of Enerplus (NYSE:ERF) (TSE:ERF). They issued a buy rating on the stock.
First Quantum Minerals (TSE:FM) was upgraded by analysts at TD Securities from a buy rating to an action list buy rating. The firm currently has C$30.00 price target on the stock, up from their previous price target of C$25.00.
Stephens began coverage on shares of Heartland Financial USA (NASDAQ:HTLF). They issued an equal weight rating on the stock.
International Petroleum (TSE:IPCO) was downgraded by analysts at GMP Securities from a hold rating to a reduce rating.
K&S (OTCMKTS:KPLUF) was upgraded by analysts at Deutsche Bank AG from a sell rating to a hold rating.
Orexigen Therapeutics (NASDAQ:OREX) had its price target lowered by S&P Equity Research from $0.15 to $0.12.
Sanofi (EPA:SAN) was given a €74.00 ($86.05) price target by analysts at Goldman Sachs Group Inc. The firm currently has a neutral rating on the stock.
YY (NASDAQ:YY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “YY Inc. is a communication social platform, which engages users in online group activities through voice, text and video. The Company’s Platform consists of YY Client, the YY.com and Duowan.com web portals, Mobile YY and Web-based YY. YY Inc. is based in Guangzhou, the People’s Republic of China. “
Zai Lab (NASDAQ:ZLAB) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
Receive News & Ratings for ACCO Brands Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACCO Brands Co and related companies with MarketBeat.com's FREE daily email newsletter.